Is Your IV Insulin Ready When and Where You Need It?

MYXREDLIN (Insulin Human) in 0.9% Sodium Chloride Injection

Ready-to-Use Premix IV Insulin from Baxter

Indication

MYXREDLIN is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

Please see the accompanying full Indication(s) and Important Risk Information and full Prescribing Information.

Available when and where you need it: A ready-to-use IV infusion helps reduce patient wait time for high-alert insulin. Myxredlin is ready to scan and hang.

Make Myxredlin part of your risk-reduction strategy

MyxBagGrabFeatCont

MYXREDLIN helps support safety with:

• Opportunity to reduce medication errors associated with compounding1,2

• Consistent, reliable concentration of a commercially prepared insulin infusion

• On-bag barcoding to help verify patient-medication association

30-Day Room Temperature Storage

• Store closer to the patient

 

• Help reduce pharmacy STAT production

 

• If needed, MYXREDLIN may be removed from the original carton and stored at room temperature up to 77°F (25°C) for up to 30 days

24-Month Refrigerated Shelf Life

• Help ensure IV insulin is available when needed, reducing the need for on-the-floor compounding practices

 

• Store MYXREDLIN in the refrigerator (36°F to 46°F [2°C to 8°C]) in the original carton to protect from light

In a review of preventable adverse drug events (ADE) associated with inpatient injectable medications,* insulin had the highest probability for a preventable adverse drug event3

*Route of administration not specified.

IV insulin ranked #1 for high-alert drugs among pharmacists and nurses4

ISMP and ASHP guidelines recommend use of a commercially prepared product instead of compounding as a risk-reduction strategy for high-alert medications.1,2

When implemented alongside existing hospital best practices, Myxredlin can help reduce errors that may result from compounding practices.1,2

It really only takes one bad outcome associated with compounding to change your mind about using a premix IV product like Myxredlin. But why would you wait for a compounding error? …Every facility doesn’t always have 24-hour pharmacy, or sometimes there’s a STAT order for insulin that needs to be filled. I do not like the idea of asking nursing to compound on the floor, especially during an emergency. Myxredlin lets us keep IV insulin in the automated dispensing cabinet.”

CHRISTUS Health, Tina Collins, PharmD, Director of Corporate Clinical Medication Safety

Ready-to-use Myxredlin (Insulin Human) can help streamline IV insulin production and reduce waste

Managing Efficiency with MYXREDLIN

Myxredlin can help
• Streamline insulin production and delivery

• Reduce expired or unused insulin waste5
- No additional costs related to disposal of preservative-free Myxredlin compared with insulin vials containing m-cresol

• Reduce risk of preventable adverse drug events associated with compounding errors1,2 and pharmacy resources spent compounding

Myxredlin has had a positive impact on our operations. Nursing staff appreciates having IV insulin available 24/7 in the automated dispensing cabinet. Pharmacy staff has been freed up to focus on compounding other products that don’t have a commercially prepared option. We’ve even improved our disposal process since we don’t have to treat the empty bags as hazardous waste.”

CHRISTUS Health, Tina Collins, PharmD, Director of Corporate Clinical Medication Safety

Switching to MYXREDLIN (Insulin Human) in 0.9% Sodium Chloride Injection can help deliver more value

Approximately 24 hours per week is spent on IV insulin preparation, according to a survey of 90 hospitals nationwide6

Myxredlin can help streamline insulin production and delivery by reducing expired insulin waste5 and may help to reduce compounding errors1,2 and pharmacy resources spent compounding.

Baxter MYXREDLIN: Specifications

Myxredlin (Insulin Human) Wholesaler Ordering Information

MYXREDLIN (Insulin Human) in 0.9% Sodium Chloride Injection

INDICATIONS AND IMPORTANT RISK INFORMATION

Indication

MYXREDLIN is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

Important Risk Information

Contraindications

• During episodes of hypoglycemia
• Hypersensitivity to insulin human or any of the excipients in MYXREDLIN

Warnings and Precautions

Hyper- or Hypoglycemia with Changes in Insulin Regimen: Carry out under close medical supervision and increase frequency of blood glucose monitoring.
• Administer MYXREDLIN intravenously ONLY under medical supervision with close monitoring of blood glucose and potassium levels. Hypokalemia may be life-threatening if not treated.
• Individualize dose based on metabolic needs, blood glucose monitoring results, and glycemic control goal. Dosage adjustments may be needed with changes in nutrition, renal, or hepatic function or during acute illness.
• Adverse reactions observed with insulin human injection include hypoglycemia, allergic reactions, weight gain and edema.
• Fluid Retention and Heart Failure with Concomitant Use of Thiazolidinediones (TZDs): Observe for signs and symptoms of heart failure; such as shortness of breath, swelling of your ankles or feet, or sudden weight gain.

Dosage and Administration

• Inspect MYXREDLIN visually before use. It should appear clear and colorless. Do not use MYXREDLIN if particulate matter or coloration is seen.
• Do not add supplementary medication or additives.
• Do not use in series connections.
• Do not shake or freeze. Discard unused portion.

Please click here for MYXREDLIN (Insulin Human) in 0.9% Sodium Chloride Injection full Prescribing Information.

Select Important Risk Information

CONTRAINDICATIONS
•During episodes of hypoglycemia
•Hypersensitivity to insulin human or any of the excipients in MYXREDLIN

Please click the Learn More button for additional Important Risk Information and accompanying Prescribing Information

Learn More